ASGCT Q1 Landscape Report Paints Positive Picture for Gene and RNA Therapy

Why It Matters

The report signals a rebounding biotech sector, where heightened investment and faster regulatory pathways could accelerate the delivery of advanced therapies to patients and create new market opportunities for investors and pharma partners.

Key Takeaways

• 42 gene, 38 RNA, 76 cell therapies approved worldwide
• Startup funding up 30% YoY; 26 startups in Q1 2026
• Over 4,200 pipelines; 4,130 gene/mod cell, 1,300 RNA
• CAR‑T leads ex‑vivo pipeline; NK and TCR therapies rise
• 60%+ gene trials now focus on non‑oncology diseases

Pulse Analysis

The ASGCT Q1 Landscape Report paints a vivid picture of a maturing gene, RNA and cell therapy ecosystem. With 42 gene therapies, 38 RNA treatments and 76 cell products already approved, the sector is moving from experimental to mainstream. The pipeline breadth is staggering—more than 4,200 candidates in pre‑clinical to registration stages, the vast majority being gene‑or cell‑based. This depth not only diversifies therapeutic options but also spreads risk across a wide array of indications, from rare genetic disorders to oncology and emerging immunological targets.

Funding dynamics underscore the market’s momentum. Startup capital rose 30% compared with Q1 2025, and the number of new entrants jumped to 26, well above the historical 5‑20 range. Such capital influx fuels early‑stage innovation, especially in CAR‑T, NK and T‑cell receptor platforms, while also supporting RNAi advances. Investors are taking note, as the influx of capital often precedes breakthrough approvals and can drive valuation uplifts for both nascent firms and established biotech players seeking strategic collaborations.

Regulatory trends further amplify optimism. Eight gene therapies received approval in the past twelve months, half in the United States, with additional clearances in China and Japan. More than 60% of current gene therapy trials now target non‑oncology diseases, reflecting a strategic shift toward chronic and rare conditions. Accelerated pathways such as Fast Track, RMAT and orphan designations are expected to streamline approvals through 2027, positioning the sector for a wave of new products that could reshape patient care and generate substantial revenue streams.